Roche today announced data from its "Addressing the Need for Advanced HPV Diagnostics," or ATHENA, trial in the US to test the ability of its PCR-based genotyping test to identify women with cervical pre-cancer missed by cytological examination with a Pap test.

The trial, which examined more than 47,000 women, demonstrated that one in 10 women age 30 years and older who had a normal Pap test but who tested positive for HPV genotypes 16 and/or 18 with Roche's Cobas 4800 HPV test, had cervical precancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.